Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention ImmunityBio Inc., the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ANKTIVA
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention ImmunityBio Inc., the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.3 for the same window. The 7 average consequence score is above the beat benchmark of 6.6 in the same window. ANKTIVA appears in 1 tracked Healthcare story from March 25, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ANKTIVA. Shared-story counts are live from our verified record — not editorial picks.
ImmunityBio Inc. has received regulatory approval for its flagship immunotherapy, ANKTIVA, in the Macau Special Administrative Region of China. This milestone marks the first international expansion for the IL-15 superagonist following its 2024 U.S. FDA approval, positioning the company to tap into the significant oncology market in the Greater Bay Area.